Legend Biotech Corp (LEGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350M 700M 1.1B Q3 '22: 27.4M Q1 '23: 36.3M Q2 '23: 73.3M Q3 '23: 96M Q4 '23: 79.4M Q1 '24: 15.5M Q2 '24: 93.3M Q3 '24: 17.4M Q4 '24: 501.1M Q1 '25: 9.4M Q2 '25: 35.3M Q3 '25: 10.5M Q4 '25: 973.5M Q3 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit Quarterly

-300M 0 300M 600M 900M Q3 '22: 1.9M Q1 '23: 723K Q2 '23: 40.7M Q3 '23: 52.5M Q4 '23: 47M Q1 '24: -33.6M Q2 '24: 47.9M Q3 '24: -35.1M Q4 '24: 431.7M Q1 '25: -60.1M Q2 '25: -59.5M Q3 '25: -102.8M Q4 '25: 854.1M Q3 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '24: -70.4M Q4 '24: -79.3M Q3 '25: -43.5M Q4 '25: -19.6M Q3 '24 Q4 '24 Q3 '25 Q4 '25

Net Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '22: -85M Q4 '22: -135.9M Q1 '23: -112.1M Q2 '23: -199.1M Q3 '23: -62.2M Q4 '23: -144.9M Q1 '24: -59.8M Q2 '24: -18.2M Q3 '24: -125.3M Q4 '24: 26.3M Q1 '25: -100.9M Q2 '25: -125.4M Q3 '25: -39.7M Q4 '25: -30.8M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Cost of Revenue Quarterly

0 50M 100M 150M Q3 '22: 25.5M Q4 '22: 23M Q1 '23: 35.6M Q2 '23: 32.7M Q3 '23: 43.5M Q4 '23: 32.4M Q1 '24: 49.1M Q2 '24: 45.4M Q3 '24: 52.5M Q4 '24: 69.4M Q1 '25: 69.5M Q2 '25: 94.9M Q3 '25: 113.3M Q4 '25: 119.5M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '22: -72.1M Q4 '22: -49.7M Q1 '23: -139.2M Q2 '23: -97.6M Q3 '23: -60.8M Q4 '23: -95.7M Q1 '24: 15.5M Q2 '24: -1.7M Q3 '24: -75.8M Q4 '24: -82M Q1 '25: -103.8M Q2 '25: -13M Q3 '25: 28.8M Q4 '25: -12.2M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '22: -74.7M Q4 '22: -56.3M Q1 '23: -143.5M Q2 '23: -103.7M Q3 '23: -66.2M Q4 '23: -100M Q1 '24: 9.3M Q2 '24: -5.1M Q3 '24: -77.9M Q4 '24: -84.4M Q1 '25: -105.8M Q2 '25: -22.3M Q3 '25: 23.8M Q4 '25: -24.6M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '23: 330.5M Q1 '24: 364M Q2 '24: 365.2M Q3 '24: 366.6M Q1 '25: 367.5M Q2 '25: 368.3M Q3 '25: 369.3M Q1 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q4 '23: -1.47 Q1 '24: -1.29 Q2 '24: -0.77 Q3 '24: -0.95 Q4 '24: -0.48 Q1 '25: -0.59 Q2 '25: -0.88 Q3 '25: -0.65 Q4 '25: -0.81 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.